Bararia A, Chakraborty P, Roy P, Chattopadhay BK, Das A, Chatterjee A, Sikdar N. Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. World J Gastroenterol 2023; 29(15): 2241-2260 [PMID: 37124888 DOI: 10.3748/wjg.v29.i15.2241]
Corresponding Author of This Article
Nilabja Sikdar, PhD, Research Scientist, Doctor, Human Genetics Unit, Indian Statistical Institute, 203, B.T. Road, Kolkata 700108, India. snilabja@isical.ac.in
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Akash Bararia, Nilabja Sikdar, Human Genetics Unit, Indian Statistical Institute, Kolkata 700108, India
Prosenjeet Chakraborty, Department of Molecular Biosciences, SVYASA School of Yoga and Naturopathy, Bangalore 560105, India
Paromita Roy, Department of Pathology, Tata Medical Center, Kolkata 700160, India
Bitan Kumar Chattopadhay, Department of General Surgery, IPGMER & SSKM Hospital, Kolkata 700020, India
Amlan Das, Department of Biochemistry, Royal Global University, Assam 781035, India
Aniruddha Chatterjee, Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9061, New Zealand
Aniruddha Chatterjee, School of Health Sciences and Technology, University of Petroleum and Energy Studies, Dehradun 248007, India
Author contributions: Bararia A and Chakraborty P wrote the first draft of the paper and constructed the flow chart and tables; Chatterjee A, Roy P, Chattopadhay B K, Das A and Sikdar N provided valuable input, suggestions, comments and guidance while writing the review manuscript and contributed to proofreading and editing; Sikdar N constructed, wrote, conceptualized, and edited the review manuscript.
Supported bythe Department of Biotechnology, Government of India Grant Sanction, Ramalingaswami Re-entry Fellowship, No. RLS/BT/Re-entry/05/2012.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nilabja Sikdar, PhD, Research Scientist, Doctor, Human Genetics Unit, Indian Statistical Institute, 203, B.T. Road, Kolkata 700108, India. snilabja@isical.ac.in
Received: November 28, 2022 Peer-review started: November 28, 2022 First decision: January 11, 2023 Revised: February 2, 2023 Accepted: March 15, 2023 Article in press: March 15, 2023 Published online: April 21, 2023 Processing time: 136 Days and 23.7 Hours
Abstract
A global increase in the incidence of pancreatic cancer (PanCa) presents a major concern and health burden. The traditional tissue-based diagnostic techniques provided a major way forward for molecular diagnostics; however, they face limitations based on diagnosis-associated difficulties and concerns surrounding tissue availability in the clinical setting. Late disease development with asymptomatic behavior is a drawback in the case of existing diagnostic procedures. The capability of cell free markers in discriminating PanCa from autoimmune pancreatitis and chronic pancreatitis along with other precancerous lesions can be a boon to clinicians. Early-stage diagnosis of PanCa can be achieved only if these biomarkers specifically discriminate the non-carcinogenic disease stage from malignancy with respect to tumor stages. In this review, we comprehensively described the non-invasive disease detection approaches and why these approaches are gaining popularity for their early-stage diagnostic capability and associated clinical feasibility.
Core Tip: Considering the limited commercial availability of cell free nucleic acids and secreted proteome-based non-invasive biomarkers it is crucial to summarize them for the proper diagnosis of pancreatic cancer and distinguish it from other benign pancreatic diseases. We also highlighted the clinical use of these non-invasive biomarkers in diagnostics. This review will successfully guide readers to address the current issues and aid in the cutting-edge development of biomarkers with higher sensitivity and specificity.
